Sponsors (30)
The bill expands and clarifies Medicare coverage for hereditary‑cancer testing, high‑risk screening, and preventive surgeries—improving access and aligning care with clinical guidelines for high‑risk beneficiaries—while increasing federal costs and creating administrative complexity that may produce implementation challenges and some access tradeoffs.
Medicare beneficiaries at elevated hereditary cancer risk (those meeting the bill's patient definition) gain covered access to guideline-recommended germline genetic testing, higher-frequency/high-risk cancer screening, and risk‑reducing surgeries that are judged reasonable and necessary.
Coverage is explicitly tied to evidence‑based oncology guidelines (e.g., NCCN, ASCO, SGO), and contractors must adopt the least restrictive guideline when conflicts exist, which promotes clinically appropriate care and expands patient access when professional organizations differ.
The bill clarifies CMS coverage and payment policy (including applying the new rules to existing screening mammography payment provisions), which should reduce prior‑authorization denials, simplify billing, and lower administrative barriers for eligible patients and providers.
Expanding Medicare coverage for genetic testing, more frequent high‑risk screening, and risk‑reducing surgeries will increase Medicare spending, which could raise federal health expenditures or put pressure on premiums/taxes and other program priorities.
Implementing guideline‑based coverage and contractor determinations may create additional administrative burden and complexity for CMS, contractors, and providers during implementation, potentially delaying claims processing or care.
Broader coverage and higher screening frequency could increase demand for specialist imaging and procedures, potentially lengthening wait times for diagnostic services for some patients.
Based on analysis of 4 sections of legislative text.
Requires Medicare to cover guideline-based hereditary cancer genetic testing, treat guideline-recommended risk‑reducing surgery as covered, and relax screening limits for mutation carriers.
Introduced July 23, 2025 by Debbie Wasserman Schultz · Last progress July 23, 2025
Requires Medicare to cover germline genetic testing for people with a personal or family history suggesting hereditary cancer when testing follows evidence-based oncology guidelines. It makes guideline-recommended risk‑reducing surgery a covered, medically necessary service for eligible beneficiaries, and it relaxes or removes routine frequency limits on certain cancer screening tests for beneficiaries found to carry hereditary cancer gene mutations, with coverage at least annually. These changes apply to items and services furnished on or after enactment.